

Leukaemia Section

Short Communication

t(3;5)(q21;q31)

Jean-Loup Huret

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France (JLH)

Published in Atlas Database: September 2013

Online updated version : <http://AtlasGeneticsOncology.org/Anomalies/t0305q21q31ID1110.html>
DOI: 10.4267/2042/53490

This article is an update of :
t(3;5)(q21;q31)/ANLL (AML; ---; not rare). Atlas Genet Cytogenet Oncol Haematol

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.
© 2014 Atlas of Genetics and Cytogenetics in Oncology and Haematology

Abstract

Review on t(3;5)(q21;q31), with data on clinics, and the genes implicated.

Clinics and pathology

Disease

Acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and myeloproliferative disorder (MPD)

Note

26 cases of t(3;5)(q21;q31) in myeloid malignancy are available (Oshimura et al., 1976; Dewald, 1984; Bitter et al., 1985; Testa et al., 1985; Werner-Favre et al., 1985; Pi and Kalousek, 1986; Smadja et al., 1986; McCarthy et al., 1987; Sharp et al., 1987; Akiyoshi et al., 1991; Katz et al., 1992; Solé et al., 1992; Secker-Walker et al., 1995; Wong and Kwong, 1995; Groupe Français de Cytogénétique Hématologique, 1996; Dong et al., 1998; Mazzella et al., 1998; Misawa et al., 1998; Green et al., 1999; Berger et al., 2006; Lugthart et al., 2010). We have excluded from this review a case of acute lymphoblastic leukemia (Chen et al., 1992).

Phenotype/cell stem origin

There was 5 M6-AMLs, 2 M4-AMLs, 10 M2-AMLs, and 6 AMLs not otherwise specified (AML-NOS), 1 myeloid metaplasia with myelofibrosis (MMM) in acute phase, another myeloproliferative

syndrome not otherwise specified, and a refractory anemia with excess of blasts in transformation (RAEB-t).

There was no reference with a previous toxic exposure.

Epidemiology

Median age was 36-38 years (range 3-85, with two pediatric cases aged 3); sex ratio was 11M/14F.

Prognosis

Data on survival is very scarce (patients alive at 3 months, 21 months, 29 months, and 30 months; and patients dead at 7 and 9 months).

Cytogenetics

Cytogenetics morphological


The t(3;5)(q21;q31) was the sole anomaly in 20 of 25 cases.

Complex karyotypes were present in 3 cases. A del(5q)-5 was found in one case, a del(7q)-7 was found in two cases, and a +8 in two cases.

Genes involved and proteins

Note

The genes involved in this translocation remain unknown.



t(3;5)(q21;q31). G- banding (left) - top three: Courtesy Christine Perot; bottom: Courtesy Francine Mugneret; and R- banding (right) - top three: Courtesy Christine Perot; bottom three: Courtesy Francine Mugneret.

References

- Oshimura M, Hayata I, Kakati S, Sandberg AA. Chromosomes and causation of human cancer and leukemia. XVII. Banding studies in acute myeloblastic leukemia (AML). *Cancer*. 1976 Aug;38(2):748-61.
- Dewald G.. Fourth International Workshop on Chromosomes in Leukemia 1982: Abnormalities of chromosome 3 among 24 patients with de novo ANLL. *Cancer Genet Cytogenet*. 1984 March 1; 11(3):306.
- Bitter MA, Neilly ME, Le Beau MM, Pearson MG, Rowley JD.. Rearrangements of chromosome 3 involving bands 3q21 and 3q26 are associated with normal or elevated platelet counts in acute nonlymphocytic leukemia. *Blood*. 1985 Dec;66(6):1362-70.
- Testa JR, Misawa S, Oguma N, Van Sloten K, Wiernik PH.. Chromosomal alterations in acute leukemia patients studied with improved culture methods. *Cancer Res*. 1985 Jan;45(1):430-4.
- Werner-Favre C, Engel E, Beris P.. Translocation t(3;5) in ANLL. *Cancer Genet Cytogenet*. 1985 Apr 1;16(3):279.
- Pi D, Kalousek DK.. Translocation t(3;5) in acute myelocytic leukemia type M2. *Cancer Genet Cytogenet*. 1986 Feb 1;20(1-2):171.
- Smadja N, Krulik M, de Gramont A, Sirinelli A, Dray C, Brissaud P, Debray J.. Translocation t(3;5) and acute nonlymphocytic leukemia. *Cancer Genet Cytogenet*. 1986 Feb 1;20(1-2):173-4.
- McCarthy CM, Cobcroft RG, Harris MG, Scott DC.. Sweet's syndrome, acute leukemia, and t(3;5). *Cancer Genet Cytogenet*. 1987 Sep;28(1):87-91.
- Sharp RA, Robertson J, Heppleston AD.. t(3;5)(q21;q31) in a myelodysplastic syndrome. *Leuk Res*. 1987;11(7):629-33.
- Akiyoshi TT, Kimura N, Uike N, Kozuru M, Tamura K, Takihara Y, Hisano S, Nishimura J, Kikuchi M.. Genotypic and cytogenetic study of acute myelocytic leukemia and chronic myelocytic leukemia in blast crisis: specific delta rearrangement pattern does not involve J delta gene locus. *Leuk Res*. 1991;15(8):683-91.
- Chen Z, Morgan R, Sandberg AA.. Non-random involvement of chromosome 5 in ALL. *Cancer Genet Cytogenet*. 1992 Jul 1;61(1):106-7.
- Katz F, Webb D, Gibbons B, Reeves B, McMahon C, Chessells J, Mitchell C.. Possible evidence for genomic imprinting in childhood acute myeloblastic leukaemia associated with monosomy for chromosome 7. *Br J Haematol*. 1992 Mar;80(3):332-6.

Sole F, Caballin MR, Coll MD, Woessner S, Besses C, Sans-Sabrafen J, Egozcue J.. Cytogenetic studies in acute nonlymphocytic leukemia. *Cancer Genet Cytogenet*. 1992 Jun;60(2):117-24.

Secker-Walker LM, Mehta A, Bain B.. Abnormalities of 3q21 and 3q26 in myeloid malignancy: a United Kingdom Cancer Cytogenetic Group study. *Br J Haematol*. 1995 Oct;91(2):490-501.

Wong KF, Kwong YL.. Complex variant t(3;5) (q21;q31), t(3;5;19)(q21;q31;p13) in acute myeloid leukemia. *Am J Hematol*. 1995 Sep;50(1):70-1.

[No authors listed]. Cytogenetic analysis in patients with primary myelodysplastic syndromes in leukaemic transformation. A report on 94 cases. Groupe Francais de Cytogenetique Hematologique (GFCH). *Hematol Cell Ther*. 1996 Apr;38(2):177-81.

Dong SY, Morgan R, Van Ness L, Georgantas D, Meloni AM, Chen Z, Sandberg AA.. Translocation(3;5)(q21-24;q31-34) in two cases of acute myeloid leukemia and in one case of thrombocytosis. *Cancer Genet Cytogenet*. 1998 Apr 15;102(2):158.

Mazzella FM, Kowal-Vern A, Shrit MA, Wibowo AL, Rector JT, Cotelingam JD, Collier J, Mikhael A, Cualing H, Schumacher HR.. Acute erythroleukemia: evaluation of 48 cases with reference to classification, cell proliferation, cytogenetics, and prognosis. *Am J Clin Pathol*. 1998 Nov;110(5):590-8.

Misawa S, Horiike S, Kaneko H, Sasai Y, Ueda Y, Nakao M, Yokota S, Taniwaki M, Fujii H, Nakagawa H, Tsuda S,

Kashima K.. Significance of chromosomal alterations and mutations of the N-RAS and TP53 genes in relation to leukemogenesis of acute myeloid leukemia. *Leuk Res*. 1998 Jul;22(7):631-7.

Green WB, Slovak ML, Chen IM, Pallavicini M, Hecht JL, Willman CL.. Lack of IRF-1 expression in acute promyelocytic leukemia and in a subset of acute myeloid leukemias with del(5)(q31). *Leukemia*. 1999 Dec;13(12):1960-71.

Berger R, Busson M, Baranger L, Helias C, Lessard M, Dastugue N, Speleman F.. Loss of the NPM1 gene in myeloid disorders with chromosome 5 rearrangements. *Leukemia*. 2006 Feb;20(2):319-21.

Lugthart S, Groschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruiters E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Kohne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Dohner K, Lowenberg B, Dohner H.. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. *J Clin Oncol*. 2010 Aug 20;28(24):3890-8. doi: 10.1200/JCO.2010.29.2771. Epub 2010 Jul 26.

This article should be referenced as such:

Huret JL. t(3;5)(q21;q31). *Atlas Genet Cytogenet Oncol Haematol*. 2014; 18(3):200-202.
